Byrne Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Byrne Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318K	Sell	1,674 -32	-2%	-$5.5K	0.17%	99
2026 Q1	$288K	Sell	1,706 -107	-6%	-$18.3K	0.17%	101
2025 Q4	$306K	Buy	1,813 +1,274	+236%	+$207K	0.17%	101
2025 Q3	$77.8K	Sell	539 -4	-0.7%	-$546	0.05%	180
2025 Q2	$68.7K	Sell	543 -10	-2%	-$1.23K	0.05%	185
2025 Q1	$70.7K	Buy	+553	New	+$75K	0.05%	173
2024 Q4	–	Sell	-852	Closed	-$120K	–	159
2024 Q3	$124K	Sell	852 -32	-4%	-$4.63K	0.08%	139
2024 Q2	$122K	Sell	884 -595	-40%	-$79.4K	0.09%	140
2024 Q1	$203K	Buy	+1,479	New	+$202K	0.14%	105
2023 Q4	–	Sell	-1,556	Closed	-$190K	–	110
2023 Q3	$190K	Hold	1,556	–	–	0.16%	108
2023 Q2	$198K	Buy	1,556 +4	+0.3%	+$520	0.13%	145
2023 Q1	$200K	Sell	1,552 -52	-3%	-$6.81K	0.14%	130
2022 Q4	$211K	Buy	1,604 +805	+101%	+$104K	0.15%	128
2022 Q3	$93K	Hold	799	–	–	0.07%	163
2022 Q2	$94K	Sell	799 -233	-23%	-$27.7K	0.07%	146
2022 Q1	$134K	Sell	1,032 -49	-5%	-$6.38K	0.08%	139
2021 Q4	$165K	Buy	+1,081	New	+$167K	0.11%	122

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Byrne Asset Management's IBB Position: Q2 2026 in Review

Byrne Asset Management reduced its iShares Biotechnology ETF (IBB) stake by 1.9% in Q2 2026, selling an estimated $5.5K and leaving 1,674 shares worth $318K. The position accounts for 0.17% of the portfolio, ranked #99.

Byrne Asset Management first reported a position in IBB in Q4 2021 and has held it in 17 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Byrne Asset Management held 1,674 shares of iShares Biotechnology ETF worth $318K as of Q2 2026.
Byrne Asset Management sold 32 iShares Biotechnology ETF shares in Q2 2026, an estimated $5.5K.
iShares Biotechnology ETF made up 0.17% of Byrne Asset Management's portfolio in Q2 2026, its #99 holding.
Byrne Asset Management first reported a position in iShares Biotechnology ETF in Q4 2021 and has held it in 17 quarters since.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.